- Home
- RFIL vs INKT Comparison
RFIL vs INKT Comparison
Compare RFIL & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RFIL | INKT |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.5M | 57.6M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RFIL | INKT |
|---|---|---|
| Price | $9.51 | $9.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $11.25 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 293.8K | 149.8K |
| Earning Date | 03-16-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $55,325,000.00 | N/A |
| Revenue This Year | $7.07 | N/A |
| Revenue Next Year | $5.72 | N/A |
| P/E Ratio | $1,203.00 | ★ N/A |
| Revenue Growth | ★ 10.22 | N/A |
| 52 Week Low | $3.39 | $6.66 |
| 52 Week High | $13.54 | $76.00 |
Technical Indicators
Market Signals| Indicator | RFIL | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 43.54 | 40.74 |
| Support Level | $9.32 | $6.80 |
| Resistance Level | $12.41 | $12.64 |
| Average True Range (ATR) | 1.39 | 0.73 |
| MACD | -0.16 | -0.13 |
| Stochastic Oscillator | 2.70 | 7.98 |
Price Performance
Historical ComparisonAbout RFIL RF Industries Ltd.
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.